Company intelligence / Profile preview

CellarisBio

San Diego, California, USAcellarisbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CellarisBio has developed the MICRO-TAG™ cell target engagement platform enabling real-time analysis of drug-target interactions within live cells. The technology supports de novo drug discovery using DNA Encoded Libraries, hit-to-lead optimization, and mechanism-of-action studies. It has been validated on challenging targets such as transcription factors, DHFR, TBL1, and KRAS. The company collaborates with academic groups and biotechs to accelerate early-stage drug discovery against previously undruggable targets.

Therapeutic areas: OncologyImmunologyOther
Modalities: Small moleculeBiologics (potential)
Industry: Biotech

Partnerships

Multiple partnerships with companies globally are mentioned but not named specifically.

Beyond the preview

Go deeper on CellarisBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellarisBio.

Explore the full profile